Roche CEO Dr. Severin Schwan Appointed IBLAC Vice Chair, Reinforcing Commitment to China with New Strategic Initiatives
Roche
Oncology Drug Research, Development, and Manufacturing
Recently, Dr. Severin Schwan, Global Chief Executive Officer of Roche, "attended virtually"The 33rd International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC).Focusing on the conference theme “New Development Paradigm and Shanghai's Leading Role in Reform and Opening-up,” Dr. Shi Wan actively offered advice and suggestions for Shanghai's development.
This marks over 20 consecutive years of Roche's participation in IBLAC, and as a long-standing friend of both the Shanghai Municipal Government and IBLAC,Dr. Schwan himself has also kept his appointment as scheduled for 12 consecutive years.This year, Dr. Severin Schwan was elected Vice Chair of the next IBLAC,We will work more closely with the Shanghai Municipal Government and all member units, making concerted efforts to advance the high-quality development of Shanghai. This serves as a strong recognition of Dr. Thomas Schwan’s longstanding, tireless dedication to sharing global perspectives and experience in support of Shanghai’s urban development and the growth of its biopharmaceutical industry.
Looking ahead, Roche will continue to support the development of Shanghai’s biopharmaceutical industry, further increase its investment in China, and fulfill its long-term commitment to the Chinese market.
2021 was not only China'sthe inaugural year of the "14th Five-Year Plan", and particularly in the "post-pandemic era"A critical juncture for the country to achieve comprehensive economic recovery.
As a major platform for China's economic development, Shanghai is expected to further drive opening-up in key industries such as biomedicine,Ignite new growth drivers for economic development, boosting the economy to achieve higher-quality development.
As a global biopharmaceutical company, Roche has accumulated extensive experience through its participation in three of the world’s leading biopharmaceutical industry clusters: the San Francisco Bay Area in the United States, Basel in Switzerland, and Singapore.
In this IBLAC report submitted by Roche, Dr. Shi Wan focused on“Develop a world-class biomedical industry cluGroup,“Building a Two-Way Channel to Connect China and the World”The theme proposes that Shanghai should focus on advancing the high-quality development of the biopharmaceutical industry from two aspects: opening-up and institutional development.
「Ten Thousand」*A Thousand Words*
Shanghai should continue to expand its opening-up and promote more proactive industrial development. While further strengthening industry-academia-research collaboration, it should optimize local clinical development and market access mechanisms to accelerate patient access to innovative products and therapies.
Shanghai should adopt a multi-pronged approach to fully unlock the potential of its biopharmaceutical industry by further strengthening intellectual property protection, enhancing biopharmaceutical manufacturing capabilities, and attracting and cultivating professional talent both domestically and internationally, thereby building a more attractive ecosystem for the biopharmaceutical sector.
As the vanguard of China's opening-up strategy and a pioneer in the innovative development of the healthcare sector, Shanghai has consistently remained at the forefront of developing biopharmaceutical industry clusters.
Currently, Shanghai has designated biomedicine as one of its three major strategic emerging industries, and it is necessary to further expand upon past successful experience to accelerate the development of the industry.
From the perspective of global practices and current practical needs, it is recommended that Shanghai formulate moreImplement targeted industrial policies to fully leverage industrial resources, drive transformation and upgrading, and build a world-class biopharmaceutical industrial cluster that is "In China, for the World".
Deeply rooted in China for 27 years, Roche has consistently upheld its long-term commitment to the country, and has been honored to participate in and witness the development of China's biopharmaceutical industry clusters. This year, Roche has invested over RMB 200 million to incubate local innovation, continuously increasing its investments in China, and steadily helping to accelerate healthcare innovation across the nation,Empowering the Development of China's Domestic Healthcare Innovation Ecosystem。
This year marks,# Roche Global 125th Anniversary，Roche Group will also make its fourth appearance at the CIIE, bringing patients in China enhanced personalized medicine experiences and comprehensive disease management solutions. Roche will continue to uphold its mission of "Doing now what patients need next",Consistently supporting the innovative development of China's biopharmaceutical industry to create a healthier, brighter future for all.。